Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2010-02-01
2011-10-11
Kifle, Bruck (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S280000
Reexamination Certificate
active
08034821
ABSTRACT:
Inhibition of protein kinases having one or more cysteine residues within the ATP binding site is effected by contacting the kinase, per se or in a cell or subject, with an inhibitory-effective amount of a compound having a heterocyclic core structure comprised of two or more fused rings containing at least one nitrogen ring atom, and an electrophilic substituent that is capable of reacting with a cysteine residue within the ATP binding site of a kinase.Preferred compounds include certain pyrrolopyrimidines and oxindoles having such an electrophilic substituent and optionally an aromatic or heteroaromatic substituent that is capable of interacting with a threonine or smaller residue located in the gatekeeper position of the kinase.Kinases lacking such cysteine residues may be engineered or modified so that they are capable of being inhibited by such compounds by replacing a valine or other amino acid residue within the ATP binding site by a cysteine residue.
REFERENCES:
patent: 5844106 (1998-12-01), Seela et al.
patent: 6376527 (2002-04-01), Goldstein et al.
patent: 2002/0013354 (2002-01-01), Cheng et al.
patent: 2002/0103245 (2002-08-01), Goldstein et al.
patent: 2002/0156114 (2002-10-01), Goldstein et al.
patent: 2003/0018051 (2003-01-01), Goldstein et al.
patent: WO 97/38983 (1997-10-01), None
patent: WO 99/06396 (1999-02-01), None
patent: WO 00/31048 (2000-06-01), None
Abiru, Seigou et al.; “Aspirin and NS-398 Inhibit Hepatocyte Growth Factor-Induced Invasiveness of Human Hepatoma Cells”; 2002,Hepatology, vol. 35, No. 5, pp. 1117-1124.
Burchat, A.F., et al.; “Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of Ick II”;Bioorganic&Medicinal Chemistry Letters; Oct. 2, 2000; pp. 2171-2174; vol. 10, No. 19.
Chenon, M.T., et al.; Carbon-13 magnetic resonance. XXV. Basic set of parameters for the investigation of tautomerism in purines established from carbon-13 magnetic resonance studies using certain purines and pyrrolo[2,3-d]pyrimidines.;Journal of the American Chemical Society; 1975; pp. 4627-4636; vol. 97, No. 16.
Dave, Chaitanya G. et al.; “Synthesis & Biological Activity of Pyrrolo[2,3-d]pyrimidines”; 1988,Indian Journal of Chemistry, vol. 27B, pp. 778-780.
Hanke, Jeffrey H. et al.; Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor; 1996,The Journal of Biological Chemistry, vol. 271, No. 2, pp. 695-701.
Liu, Yi et al.; “Structural basis for selective inhibition of Src family kinases by PP1”; 1999,Chemistry&Biology, vol. 6, No. 9, pp. 671-678.
Schindler, Thomas et al.; “Crystal Structure of Hck in Complex with a Src Family-Selective Tyrosine Kinase Inhibitor”; 1999,Molecular Cell, vol. 3, pp. 639-648.
Stevenson, Marry Ann et al.; “Salicylic Acid and Asprin Inhibit the Activity of RSK2 Kinase and Repress RSK2-Dependent Transcription of Cyclic AMP Response Element Binding Protein- and NF-kB-Responsive Genes”; 1999,The Journal of Immunology, pp. 5608-5616.
Tatton, Louise et al.; “The Src-selective Kinase Inhibitor PP1 Also Inhibits Kit and Bcr-Abl Tyrosine Kinases”; 2003,The Journal of Biological Chemistry, vol. 278, No. 7, pp. 4847-4853.
Zhu, Xiaotian et al.; “Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors”; 1999,Structure, vol. 7, No. 6, pp. 651-661.
Cohen Michael
Shokat Kevan
Taunton, Jr. John William
Zhang Chao
Kifle Bruck
Kilpatrick Townsend & Stockton LLP
The Regents of the University of California
LandOfFree
Selective serine/threonine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective serine/threonine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective serine/threonine kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4275003